Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB) |
 |
 |
| By M.E.Garza |
| Friday, 12 June 2009 20:48 |
|
Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
TRT: Approximately 45 Minutes BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the FDA delay, the flu pandemic and the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and interesting nuggets of new information.
about 8 hours ago
Watson Provides Update on Generic Lidoderm® Application; Gilead Soars On "Striking" Clinical Trial Data: Below i... http://t.co/IbLYNqgb
about 16 hours ago
Shares of $IDIX drop slightly after compelling new data from rival Gilead ($GILD) puts prospects for IDIX's hepatitis C drug in question.
about 1 day ago
Medgenics has Key to Protein Therapy Market: Medgenics (NASDAQ: MDGN) has what I believe to be the most disrupti... http://t.co/c3IBIWYR
about 1 day ago
Stocks Vacillate To Mixed Finish; Some Leaders Rally http://t.co/dtOQTRgh
about 1 day ago
Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR: Belo... http://t.co/a7IlIvbS
about 1 day ago
Athersys $ATHX gets grant to study traumatic brain injury http://t.co/mnZTsxXx
about 1 day ago
Watching: San Antonio patients help test new 'spray-on skin' for burns http://t.co/fzKA9B23
about 1 day ago
OncoSec's President and CEO explains his firm's ambitious list of milestones for 2012: During the past few sessi... http://t.co/fKOMc1TM
Free Phone Trade Alerts
